Online inquiry

IVTScrip™ mRNA-Anti-MAG, GSK-249320(Cap 1, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ7896MR)

This product GTTS-WQ7896MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets MAG gene. The antibody can be applied in Stroke research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001199216.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4099
UniProt ID P20916
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MAG, GSK-249320(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ7896MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2452MR IVTScrip™ mRNA-Anti-TSLP, AMG 157(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA AMG 157
GTTS-WQ5299MR IVTScrip™ mRNA-Anti-ALCAM, CD166 AADC(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CD166 AADC
GTTS-WQ1057MR IVTScrip™ mRNA-Anti-TNFRSF10B, ABBV-621(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ABBV-621
GTTS-WQ6379MR IVTScrip™ mRNA-Anti-Factor IX substitute, CSL654(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CSL654
GTTS-WQ4191MR IVTScrip™ mRNA-Anti-IL2RA, BIIB019(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA BIIB019
GTTS-WQ1702MR IVTScrip™ mRNA-Anti-Dabigatran, aDabi-Fab(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA aDabi-Fab
GTTS-WQ5312MR IVTScrip™ mRNA-Anti-ALCAM, CD166 AADC(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CD166 AADC
GTTS-WQ5200MR IVTScrip™ mRNA-Anti-CD22, CAT-8015(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CAT-8015
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW